| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 12/27/2006 | CN1883477A Pharmaceutical composition for treating hypertension and cardiovascular disease |
| 12/27/2006 | CN1883461A Sustained-releasing oral mucosa medicinal film |
| 12/27/2006 | CN1883456A Flavor-hidden pharmaceutical granule, preparation method and use thereof |
| 12/27/2006 | CN1883453A An angiogenesis inhibitor and synergist thereof co-carried sustained-releasing anticancer medicinal injection |
| 12/27/2006 | CN1883452A An angiogenesis inhibitor and synergist thererof co-carried sustained-release anticancer agent |
| 12/27/2006 | CN1883451A A sustained-release anticancer injection containing angiogenesis inhibitor and synergist thereof |
| 12/27/2006 | CN1291986C Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions |
| 12/27/2006 | CN1291757C Remedy for inflammatory bowel diseases |
| 12/27/2006 | CN1291756C Blood cell production via activation of hemeglobin scavenger receptor |
| 12/27/2006 | CN1291718C Remedy for acute myocardial infarction |
| 12/26/2006 | US7153943 Derivatives of growth hormone and related proteins, and methods of use thereof |
| 12/26/2006 | US7153887 Treatment anti-neutrophil cytoplasmic antibodies-associated vasculitis in a patient resistant to corticosteroid treatment by administering gusperimus or its salt in cycles |
| 12/26/2006 | US7153885 Stolonoxides |
| 12/26/2006 | US7153881 Compounds acting as melanocortin receptor ligands |
| 12/26/2006 | US7153877 Chromium bound to niacin and three compounds from the group consisting of (-) hydroxycitric acid, zinc (particularly zinc methionine), trans-reseveratrol, gymnernic acid, selenium, an anthocyanidin, allicin, and fenugreek. |
| 12/26/2006 | US7153862 αv integrin receptor antagonists |
| 12/26/2006 | US7153856 Orally administering N-(2-chloro-6-methylphenyl)-2-[4-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-6-ylamino]thiazole-5-carboxamide for treating cancer |
| 12/26/2006 | US7153833 Therapeutic uses of SMR1 peptides |
| 12/26/2006 | US7153826 Cyclic peptide antibiotics including the loloatins are effective in the treatment of rosacea, particularly when administered in conjunction with an antibiotic such as metronidazole that is effective against anaerobic bacteria. |
| 12/26/2006 | US7153825 Administering an exendin modified with a polyethylene glycol, gelatin and/or albumin to increase its biological half-life; treating hyperglucagonemia and diabetes, especially type II diabetes |
| 12/26/2006 | US7153824 Inhibitors of phosphodiesterases in infertility |
| 12/26/2006 | US7153649 Applying stresses to blood sampling |
| 12/26/2006 | US7153515 Method of preventing T cell-mediated responses by the use of the major histocompatibility complex class II analog protein (map protein) from Staphylococcus aureus |
| 12/26/2006 | US7153514 Use of botulinum toxin therapy for prostatic hyperplasia and related disorders |
| 12/26/2006 | US7153507 A human monoclonal antibody specifically binds to human IL-15 and to inhibit IL-15-induced proinflammatory effects; tumor necrosis factor; antiinflammatory, -arthritic, -carcinogenic, proliferative agents; rheumatic diseases; transplants |
| 12/26/2006 | US7153499 Promoting differentiation and maturation of immature dendritic cells in a regional lymph node (especially by administering a natural cytokine mixture parilymphatically) so that the cells deliver T-cell antigen to effect immunization |
| 12/26/2006 | US7153258 Cardiac support disease with anti-fibrosis coating |
| 12/21/2006 | WO2006135693A2 Direct compression formulation of dpp-iv inhibitors and glitazones, and process |
| 12/21/2006 | WO2006135636A2 Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators |
| 12/21/2006 | WO2006135621A2 Method for renin-angiotensin-aldosterone system activation and control thereof |
| 12/21/2006 | WO2006135109A1 Method for treatment of proliferative disease utilizing inhibition of formation of synoviolin homooligomer |
| 12/21/2006 | WO2006135069A1 Osteoclast differentiation/formation inhibitor, and screening method for prophylactic or therapeutic agent for metabolic bone disorder |
| 12/21/2006 | WO2006135027A1 Agent for treatment of wound and/or promotion of wound healing |
| 12/21/2006 | WO2006134692A1 Angiogenetic agent containing adrenomedulin as the active ingredient |
| 12/21/2006 | WO2006134160A2 Synergistic mixtures of aromatic alcohols and derivatives thereof and tropolone (derivatives) |
| 12/21/2006 | WO2006133942A1 NOVEL SALT FORM OF A β2 -ADRENERGIC AGONIST QUINOLIN-2-ONE DERIVATIVE |
| 12/21/2006 | WO2006121666A3 Delivery of tigecycline in the presence of warfarin |
| 12/21/2006 | WO2006103407A3 New pharmaceutical compositions useful in the treatment of migraine |
| 12/21/2006 | WO2006089005A3 Combination of selective factor viia and/or xia and plasma kallikrein inhibitors |
| 12/21/2006 | WO2006050420A3 Chimeric immunogens that comprise ovalbumin |
| 12/21/2006 | WO2006021443A3 Composition comprising an at1 receptor blocker and a macrolide t-cell immunomodulator |
| 12/21/2006 | WO2005118009A3 Transdermal delivery system for treatment of cognitive disorders |
| 12/21/2006 | US20060288434 Inhibiting angiogenesis in a mammal by administering an antibody which specifically binds to EphriniB2 or EphB4; cardiovascular disorders |
| 12/21/2006 | US20060287400 benign prostatic hyperplasia, prostate intraepithelial neoplasia (PIN), or an abnormally high level of circulating prostate specific antibody (PSA), |
| 12/21/2006 | US20060287389 Phenethanolamine derivatives for treatment of respiratory diseases |
| 12/21/2006 | US20060287378 Novel pyrroles and imidazoles |
| 12/21/2006 | US20060287367 Pyridoxamine for the treatment of diabetic kidney disease |
| 12/21/2006 | US20060287349 Benzimidazolyl- or N-hetero analog derivatives of 4-aza-5 alpha -androstan-3-ones, e.g., beta -(1H-imidazo[4,5-c]pyridin-2-yl)-4-methyl-4-aza-5 alpha -androst-1-en-3-one; treatment of conditions caused by androgen deficiency |
| 12/21/2006 | US20060287325 Combinations of paroxetine and 2-(r)-(4-fluoro-2-methyl-phenyl)-4-(s)-((8as)-6-oxo-hexahydro-pyrrolo'1,2-a!-pyrazin-2-yl)-piperidine-1-carboxylicacid'1-(r)-(3,5-bis-trifluoromethyl-phenyl)- |
| 12/21/2006 | US20060287299 Combination therapy for dementia, depression and apathy |
| 12/21/2006 | US20060287286 Prophylaxis of respiratory disorders and therapy, also metod of synthesis and composition with PDE4 inhibitor, corticosteroid hibitor or anticholinergic agent |
| 12/21/2006 | US20060287284 Pharmaceutical composition combining tenatoprazole and an anti-inflamatory agent |
| 12/21/2006 | US20060287281 Phosphohalohydrins, process for the production thereof and use thereof |
| 12/21/2006 | US20060287276 administering methyl alpha manno-oligosaccharide and proanthocyanidins to treat enteric disorders selected from gastroenteritis, ulcerative colitis, diarrhoeal disease caused by pathogenic bacteria adhesion to mammalian intestinal epithelial cells |
| 12/21/2006 | US20060287259 Compositions and methods for combined therapy of disease |
| 12/21/2006 | US20060287258 administering to the female an antibody that reduces the effect of prokineticin 1 on a prokineticin receptor to treat endometriosis; gonadotropin releasing hormone (GnRH) antagonist is selected from teverelix, abarelix, cetroelix or ganirelix antagonises the estrogen receptor |
| 12/21/2006 | US20060287251 Combination therapy for glycaemic control |
| 12/21/2006 | US20060287245 Anti-tumor agents |
| 12/21/2006 | US20060287241 Combination comprising N-(3-methoxy-5-methylpyrazin-2yl)-2-(4-[1,3,4-oxadiazol-2-y1]pyridine-3-sulphonamide and an lhrh analogue and/or bisphosphonate |
| 12/21/2006 | US20060287230 Compositions which can be used for regulating the activity of parkin |
| 12/21/2006 | US20060287225 injecting an alpha-v. beta 3 or alpha-v, beta 5 inhibitor into the vitreous body of the eye; angiogenesis inhibition; diabetic retinopathy, macular degeneration, myopia, ocular histoplasmosis; (2S)-2-benzyloxycarboxamido-3-(2-guanidinomethyl-1,4-benzodioxan-6-yl)propionic acid |
| 12/21/2006 | US20060286157 Protein mixtures for wound healing |
| 12/21/2006 | US20060286105 Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency |
| 12/21/2006 | US20060286043 Delivery of antihistamines through an inhalation route |
| 12/21/2006 | US20060286042 Condensation aerosol for delivery of a drug selected from the group consisting of zaleplon, zolpidem and zopiclone |
| 12/21/2006 | CA2611481A1 Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators |
| 12/21/2006 | CA2610412A1 Direct compression formulation of dpp-iv inhibitors and glitazones, and process |
| 12/20/2006 | EP1734120A2 Reagents and methods for identifying and modulating expression of genes regulated by CDK inhibitors |
| 12/20/2006 | EP1734051A2 Composition and methods for the diagnosis of tumours |
| 12/20/2006 | EP1734040A1 Substituted quinazoline or pyridopyrimidine derivative |
| 12/20/2006 | EP1733743A1 Preventives/remedies for cancer |
| 12/20/2006 | EP1733740A1 Therapeutic agent for auris interna disorder containing il-6 antagonist as active ingredient |
| 12/20/2006 | EP1733739A1 sFRP EXPRESSION POTENTIATING AGENT |
| 12/20/2006 | EP1733738A1 Method of preventing ultraviolet ray-induced apoptosis |
| 12/20/2006 | EP1733737A1 Axon regeneration promoter |
| 12/20/2006 | EP1733734A2 Placental alkaline phosphatase to control diabetes |
| 12/20/2006 | EP1733732A1 Insulin resistance improving agent |
| 12/20/2006 | EP1733726A1 Pharmaceutically active isoindoline derivatives |
| 12/20/2006 | EP1733725A1 Farmaceutical formulations comprising at least one HIV protease inhibiting compound |
| 12/20/2006 | EP1733723A1 Medicine capable of inhibiting activation of transcription factor klf5 |
| 12/20/2006 | EP1733722A1 Memory fixation accelerator |
| 12/20/2006 | EP1732604A2 Methods of treating hiv infection |
| 12/20/2006 | EP1732600A2 Uses of anti-ctla-4 antibodies |
| 12/20/2006 | EP1732591A2 Combined immunotherapy of fusion cells and interleukin-12 for treatment of cancer |
| 12/20/2006 | EP1732583A1 Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor |
| 12/20/2006 | EP1732575A1 Strontium-containing compounds for use in the prevention or treatment of necrotic bone conditions |
| 12/20/2006 | EP1732574A1 The use of o-atp for the treatment of diseases involving angiogenesis |
| 12/20/2006 | EP1732569A1 Use of adefovir or tenofovir for inhibiting mmtv-like viruses involved in breast cancer and primary biliary cirrhosis |
| 12/20/2006 | EP1732567A1 Use of a phenothiazine derivative for preventing and/or treating hearing loss |
| 12/20/2006 | EP1732542A2 Use of metronidazole for preparing a pharmaceutical composition for treating a cutaneous vascularisation disorder |
| 12/20/2006 | EP1732540A1 Oral health care drink and method for reducing malodors |
| 12/20/2006 | EP1732527A2 Use and administration of bacterial efflux pump inhibitors |
| 12/20/2006 | EP1732524A2 Methods and compositions for treatment of ion imbalances |
| 12/20/2006 | EP1732523A1 Ion binding polymers and uses thereof |
| 12/20/2006 | EP1732516A1 Ion binding compositions |
| 12/20/2006 | EP1732500A2 Cosmetic composition and method for retarding hair growth |
| 12/20/2006 | EP1732486A1 Drug-enhanced adhesion prevention |
| 12/20/2006 | EP1438310B1 Beta-carbolin derivatives as ptp-inhibitors |
| 12/20/2006 | EP1392314B1 NOVEL USE OF 2-[2-Ethoxy-5-(4-methyl-piperazin-1-sulfonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-on |
| 12/20/2006 | EP1379235B1 Compositions and methods for enhancing paracellular permeability across epithelial and endothelial barriers |